A5027892519- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Cancer, Lipids, and Metabolism
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Organ Transplantation Techniques and Outcomes
- Renal and Vascular Pathologies
- Organ Donation and Transplantation
- Urologic and reproductive health conditions
- Epigenetics and DNA Methylation
- Pediatric Urology and Nephrology Studies
- Testicular diseases and treatments
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Renal Diseases and Glomerulopathies
- Pharmacological Effects and Toxicity Studies
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
Yamagata University
2016-2025
Fukuoka University Hospital
2024-2025
Hokkaido University
2024
Akita University
2011-2023
Hirosaki University
2005-2023
Tsukuba University of Technology
2023
Yamagata University Hospital
2020-2023
Japanese Urological Association
2013-2020
Miyagi Prefectural Hospital Organization
2020
DMG Mori (Japan)
2018
Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall are limited by resistance.
Background. A body-weight-based dose of tacrolimus often results in marked individual diversity blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) 3A5 and p-glycoprotein encoded by CYP3A5 MDR1 (ABCB1), respectively, having multiple single nucleotide polymorphisms. In this study, we genotyped A6986G, G2677(A/T), C3435T polymorphisms investigated the association between these pharmacokinetics renal transplant recipients. Methods. Thirty consecutive recipients were...
LBA1 Background: Platinum-based chemotherapy is an active 1L regimen for advanced UC; however, progression-free survival (PFS) and overall (OS) are generally short because of resistance. This randomized, phase 3 trial (JAVELIN Bladder 100; NCT02603432) evaluated avelumab (anti–PD-L1) as maintenance therapy following response or stable disease with platinum-based in patients UC. Methods: Eligible unresectable locally metastatic UC without progression after 4-6 cycles gemcitabine either...
Immune-combinations have recently become the standard first-line treatment for patients with metastatic renal cell carcinoma (mRCC). This study evaluated applicability of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model in predicting outcomes treated either immune-oncologic drug doublet (IO-IO) or tyrosine kinase inhibitor combinations (IO-TKI). A secondary objective to compare effectiveness IO-IO versus IO-TKI within IMDC groups over a short follow-up...
The glutathione peroxidase 1 gene (GPX1) and the manganese superoxide dismutase (MnSOD) encode main antioxidant enzymes that detoxify endogenous reactive oxygen species involved in carcinogenesis. Polymorphisms of GPX1 MnSOD genes, risk transitional cell cancer bladder were tested.Genotypes leucine (Leu) to proline (Pro) polymorphism at codon 198 GPX1, alanine (Ala) Valine (Val) exon 2 isoleucine threonine 56 determined by a polymerase chain reaction-restriction fragment length technique 213...
Abstract Background To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients a high risk localized prostate cancer (PCa). Methods Complete 6 cycles (30 mg/m 2 ) (560 mg) were given to 18 PCa prostatectomy. Subsequently, clinical pathological outcomes analyzed. Results No had severe adverse events during therapy, hence they treated Two...
In the JAVELIN Bladder 100 phase 3 trial, avelumab first-line maintenance + best supportive care (BSC) prolonged overall survival (OS) and progression-free (PFS) versus BSC alone in patients with advanced urothelial carcinoma (advanced UC) without progression after platinum-based chemotherapy. To report post hoc analyses of subgroups defined by duration chemotherapy interval before maintenance. Patients UC four to six cycles a 4–10-wk (n = 700) were randomized receive or alone. Subgroups...
Abstract PTEN is a tumor suppressor gene mutated in many human cancers. We used the Cre-loxP system to generate an urothelium-specific null mutation of Pten mice [FabpCrePtenflox/flox (FPtenflox/flox) mice]. Histologic examination revealed that all FPtenflox/flox exhibited urothelial hyperplasia which component cells showed enlarged nuclei and increased cell size. With time, 10% spontaneously developed pedicellate papillary transitional carcinomas (TCC). This type also arose treated with...
The present study investigated the incidence of posttransplant diabetes mellitus (PTDM) and calculated risk developing PTDM under a tacrolimus-based immunosuppression based on clinical characteristics, tacrolimus pharmacokinetics, genetic polymorphisms related to pharmacokinetics or mellitus.Seventy nondiabetic adult kidney recipients were studied. Patients with continuous high plasma glucose levels, over 6.5 mg/dl hemoglobin A1c, requiring insulin and/or oral antidiabetic agents for more...
Aim: Tacrolimus is a substrate of CYP3A4 and CYP3A5. The present study investigated the impact CYP3A4*1/*1G polymorphism compared with CYP3A5 genotypes on dose-adjusted pharmacokinetics tacrolimus. effects variability in tacrolimus among patients CYP3A5*1 allele (CYP3A5 expresser) those CYP3A5*3/*3 genotype (nonexpresser) were also studied. Materials & methods: A total 136 renal allograft recipients given repeated doses every 12 h. On day 28 after transplantation, blood concentrations...
Dietary patterns including high-fat diet (HFD) and high-carbohydrate (HCD) play an important role in prostate cancer progression. However, which of these diets have the greatest effect on tumor progression its underlying mechanisms remains unclear.We investigated effects different cell growth relevant circulating factors serum insulin, factors, inflammatory cytokines using vivo ex model.The LNCaP xenograft was significantly higher HFD group than HCD control (CD) groups (P = 0.01; vs. HCD, P...
Fibroblast growth factor-inducible 14 (Fn14), a transmembrane receptor binding to the multifunctional cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK), is known modulate many cellular activities including cancer progression. Here, we demonstrated significant role Fn14 in invasion, migration and proliferation androgen-independent prostate (AIPC) cells. its ligand TWEAK were highly expressed two AIPC cell lines, DU 145 PC-3, whereas expression was androgen-sensitive LNCaP...
This study investigated pharmacokinetic and pharmacogenetic differences between a modified-release once-daily formulation of tacrolimus (Tac-QD) the original requiring twice-daily intake (Tac-BID) in de novo renal transplant recipients.Forty-seven 25 patients who received Tac-BID Tac-QD, respectively, were enrolled. The pharmacokinetics CYP3A5 6986A>G ABCB1 3435C>T pharmacogenetics each analyzed on day 28 posttransplantation.The dose-adjusted trough level (C0) area under concentration-time...
487 Background: The phase 3 JAVELIN Bladder 100 trial (NCT02603432) showed significantly longer overall survival (OS) with avelumab + best supportive care (BSC) vs BSC alone in patients (pts) advanced UC that had not progressed 1L platinum-containing chemotherapy. Avelumab maintenance is now considered standard of treatment guidelines. We report data ≥2-years follow-up all pts (additional 19 months from the initial analysis). Methods: Pts unresectable locally or metastatic without disease...
Abstract CCND1 mRNA is alternatively spliced to produce 2 transcripts, and the splicing pattern may be modulated by a frequent A 870 G single‐nucleotide polymorphism within conserved splice donor site of exon 4. Several studies have suggested significant association between genotype onset or progression various cancers. To investigate correlation with genetic susceptibility PCa its disease status, we examined in 214 cases PCa, 234 BPH 254 male controls. The allele was more frequently...
Purpose The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression response to treatment those patients may also be defined by host genetic factors. In this study, we evaluated polymorphisms as predictors cancer. Patients Methods One hundred eleven with bone metastasis at diagnosis were enrolled in study. Thirteen genotyped using polymerase chain...
What's known on the subject? and What does study add? Active surveillance has been widely accepted as a treatment tool for low‐risk prostate cancer, use of Prostate Cancer Research International: Surveillance ( PRIAS ) criteria can select smaller less aggressive tumours in disease. The shows pathological outcomes radical prostatectomy patients with disease who met criteria. It found that ∼20% had unfavourable features only 30% satisfied insignificant cancer p T 2 stage, G leason score ≤6...
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin 1 (mTORC1) signaling pathway is aberrantly activated in renal cell carcinoma (RCC). We previously demonstrated glycogen synthase kinase-3β (GSK-3β) positively regulated RCC proliferation. aim this study was to evaluate the role GSK-3 PI3K/Akt/mTORC1 and regulation downstream substrates, eukaryotic translation initiation factor 4E-binding protein (4EBP1), ribosomal S6 kinase (S6K), (S6RP).We used human lines (ACHN, Caki1,...